The genus Dragmatucha Meyrick is reviewed and 11 species of a total of 13 are described as new. The new species originate from the Democratic Republic of Congo, Ghana, Kenya, and Uganda. Based on morphological characters, especially the color pattern of both wings, the genus is divided into two species-groups: the proaula species-group with five species (D. proaula Meyrick, 1908; D. galbinea Park, sp. nov.; D. kabarolensis Park, sp. nov.; D. saltualis Park, sp. nov. and D. vittatella Park, sp. nov.) and the hispidula species-group with eight species (D. hispidula Park, 2018; D. goniotes Park, sp. nov.; D. cochliana Park, sp. nov.; D. pedalis Park, sp. nov.; D. ghanaensis Park, sp. nov.; D. crinifrutalis Park, sp. nov.; D. dizostera Park, sp. nov. and D. kakumensis Park, sp. nov.). Adults and male genitalia of all new species are illustrated, but female genitalia are provided only for D. ghanaensis Park, sp. nov. and D. kakumensis Park, sp. nov. When fresh material was available, the analysis of COI sequences was undertaken.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.11646/zootaxa.4786.2.1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary cutaneous carcinosarcoma treated with Mohs micrographic surgery: A case report and review of the literature.
JAAD Case Rep
January 2025
Department of Dermatology, University of California San Diego, San Diego, California.
Pivotal Trial Toward Effectiveness of Self-administered OCT in Neovascular Age-related Macular Degeneration. Report 2-Artificial Intelligence Analytics.
Ophthalmol Sci
November 2024
Notal Vision Inc., Manassas, Virginia.
Purpose: To validate the performance of the Notal OCT Analyzer (NOA) in processing self-administered OCT images from an OCT system designed for home use (home OCT [HOCT]) as part of a pivotal study aimed at achieving de novo United States Food and Drug Admininstration marketing authorization.
Design: A prospective quantitative cross-sectional artificial intelligence study.
Participants: The study enrolled adults aged ≥55 years diagnosed with neovascular age-related macular degeneration (nAMD) in ≥1 eligible eye with a best-corrected visual acuity of 20/320 or better.
Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development.
ACS Med Chem Lett
January 2025
Discovery Biology, PMV Pharmaceuticals, Inc., 400 Alexander Park Drive, Suite 301, Princeton, New Jersey 08540, United States.
p53 is a potent transcription factor that is crucial in regulating cellular responses to stress. Mutations in the gene are found in >50% of human cancers, predominantly occurring in the DNA-binding domain (amino acids 94-292). The Y220C mutation accounts for 1.
View Article and Find Full Text PDFA study on the measurement of the reference range of the whole blood viscosity in Thoroughbred horses.
Vet Med (Praha)
November 2024
Department of Veterinary Surgery, College of Veterinary Medicine, Jeonbuk National University, Republic of Korea.
This study aimed to measure the whole blood viscosity (WBV) in racehorses using a new viscometer and establish reference values, as well as to investigate the correlation between the WBV and the haematological parameters and serum chemistry. WBV measurements were conducted on 51 Thoroughbred horses using a novel U-shaped scanning capillary-tube viscometer. The reference values for the WBV were determined at various shear rates ranging from 1 s to 1 000 s.
View Article and Find Full Text PDFTolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18-35 Years: A Pooled Database Analysis.
Kidney Med
January 2025
Otsuka Pharmaceutical Development & Commercialization, Inc, Rockville, MD.
Rational & Objective: Data are limited regarding the long-term efficacy of tolvaptan in adults aged 18-35 years with autosomal dominant polycystic kidney disease (ADPKD) at increased risk of rapid progression. We assessed the effects of tolvaptan within a larger population of younger adults and over longer follow-up than individual clinical trials could provide.
Study Design: Pooled database study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!